samedan logo
home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


Jasmin Collier




Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
Two-Photon Microscopy

The Next Step

A plethora of options have emerged to improve imaging capabilities for microscopists. Laser Quantum’s Andrew Wells explains the change in the priorities of manufacturers of laser equipment, and discusses the benefits of using ultra-fast lasers.

eHealth Revolution

From the Outside

Innovation from external sources has the potential to revolutionise the biopharma industry. Dr Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré andDr Richard Beetz at Arthur D. Little suggest that by embracing the digital, a positive change could be created for patient care, even if it means advances in other areas lose pace.

  BioResearch and Innovation
Liquid Biopsies

Translating Research into Reality: Part 1

As DNA sequencing looks increasingly towards the use of liquid biopsies, the industry moves ever-closer to developing personalised treatment for all patients. Paul Elvin at Aptus Clinical explains the need to target specific mutations, and the effect that new ctDNA analysis may have on patients and developers alike.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


Industry Events

The European Prefilled Syringes Summit

7-8 September 2016, London, UK

ACI’s European Prefilled Syringes Summit will be taking place in London, UK, on the 7th – 8th September, 2016. The two day event will provide an exclusive platform for collaboration and discussion between a variety of industry perspectives including manufacturers, suppliers, academia and regulators homing in on the latest opportunities arising from new Biological Medicines. The aim is to identify potential solutions, future work programmes and productive partnerships that overcome the key regulatory challenges and facilitate minimizing risk within the supply chain promoting access to safe and effective biologicals.
More info >>

News and Press Releases

CPhI’s Pre-Connect Congress outlines current trends in pharma

Patient centricity, combination products, packaging innovation and biotherapeutics showing promise at the forefront of the industry’s development
More info >>

air transport logo


White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement